Histogenics (HSGX) Receiving Somewhat Favorable Press Coverage, Report Shows

News articles about Histogenics (NASDAQ:HSGX) have trended somewhat positive on Monday, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Histogenics earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.5897876606545 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

HSGX traded down $0.05 on Monday, reaching $2.75. The company had a trading volume of 2,666 shares, compared to its average volume of 131,670. The company has a market capitalization of $80.32, a P/E ratio of -2.81 and a beta of 1.68. Histogenics has a 52-week low of $1.59 and a 52-week high of $3.35.

How to Become a New Pot Stock Millionaire

Histogenics (NASDAQ:HSGX) last announced its earnings results on Thursday, March 15th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.05. research analysts anticipate that Histogenics will post -0.68 EPS for the current year.

A number of equities research analysts have recently issued reports on the stock. ValuEngine raised shares of Histogenics from a “strong sell” rating to a “sell” rating in a report on Monday, April 2nd. Canaccord Genuity reissued a “buy” rating and issued a $4.00 price target on shares of Histogenics in a report on Thursday, December 21st. Zacks Investment Research raised shares of Histogenics from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Histogenics in a report on Monday, March 19th.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3343617/histogenics-hsgx-receiving-somewhat-favorable-press-coverage-report-shows.html.

Histogenics Company Profile

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Insider Buying and Selling by Quarter for Histogenics (NASDAQ:HSGX)

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Itau Corpbanca  Hits New 52-Week High and Low at $15.79
Itau Corpbanca Hits New 52-Week High and Low at $15.79
Dynamic Materials  Sets New 52-Week High and Low at $30.10
Dynamic Materials Sets New 52-Week High and Low at $30.10
Del Taco Restaurants  Rating Increased to Buy at Zacks Investment Research
Del Taco Restaurants Rating Increased to Buy at Zacks Investment Research
Luminex  Upgraded at ValuEngine
Luminex Upgraded at ValuEngine
American Express  Given New $113.00 Price Target at Barclays
American Express Given New $113.00 Price Target at Barclays
ADT  Upgraded to “Hold” by ValuEngine
ADT Upgraded to “Hold” by ValuEngine


Leave a Reply

© 2006-2018 Ticker Report. Google+.